Kevin Fitzgerald
Plus aucun poste en cours
Profil
Kevin Fitzgerald is the founder of Isogenica Ltd.
which was founded in 2000, where he held the title of Chief Executive Officer from 2009 to 2013.
He also held the position of Chief Executive Officer at F-Star Biotechnologische Forschungs-.
Und Entwicklungsges MBH from 2009 to 2012.
Additionally, he was the Chief Executive Officer & Director at Activiomics Ltd., Chief Operating Officer at Altimmune UK Ltd., and Principal at Actinova Ltd.
He holds a doctorate from the University of Cambridge and an MBA from the University of Aston.
Anciens postes connus de Kevin Fitzgerald
| Sociétés | Poste | Fin |
|---|---|---|
Activiomics Ltd.
 Activiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Activiomics Ltd. develops innovative technologies that utilize mass spectrometry to interrogate and interpret the activity of cellular signaling pathways. It offers phosphoproteomics for biomaker discovery and drug profiling. The company was founded by Bart Vanhaesebroeck and Pedro Rodriguez Cutillas in 2009 and is headquartered in London, the United Kingdom. | Directeur Général | 04/03/2014 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | President | 14/05/2012 |
Altimmune UK Ltd.
 Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Directeur des opérations | - |
Actinova Ltd.
 Actinova Ltd. Pharmaceuticals: MajorHealth Technology Part of Active Biotech AB, Actinova Ltd. is a British company that provides research and development services to the biotechnology sectors and also develops drugs and vaccines. The company is based in Cambridge, UK. | Corporate Officer/Principal | - |
Isogenica Ltd.
 Isogenica Ltd. Miscellaneous Commercial ServicesCommercial Services Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom. | Fondateur | - |
Formation de Kevin Fitzgerald
| University of Cambridge | Doctorate Degree |
| University of Aston | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
Altimmune UK Ltd.
Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Health Technology |
Isogenica Ltd.
Isogenica Ltd. Miscellaneous Commercial ServicesCommercial Services Isogenica Ltd. provides research and development services in the fields of new peptide, antibody and other polypeptide drug candidates. It offers llamdA System, Xab System and 4D Fab System. The company was founded by Kevin Fitzgerald in 2000 and is headquartered in Little Chesterford, the United Kingdom. | Commercial Services |
Actinova Ltd.
Actinova Ltd. Pharmaceuticals: MajorHealth Technology Part of Active Biotech AB, Actinova Ltd. is a British company that provides research and development services to the biotechnology sectors and also develops drugs and vaccines. The company is based in Cambridge, UK. | Health Technology |
Activiomics Ltd.
Activiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Activiomics Ltd. develops innovative technologies that utilize mass spectrometry to interrogate and interpret the activity of cellular signaling pathways. It offers phosphoproteomics for biomaker discovery and drug profiling. The company was founded by Bart Vanhaesebroeck and Pedro Rodriguez Cutillas in 2009 and is headquartered in London, the United Kingdom. | Commercial Services |
